140 related articles for article (PubMed ID: 31111505)
1. Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.
Wicha SG; Mundkowski RG; Klock A; Hopt UT; Drewelow B; Kloft C; Wellner UF; Keck T; Wittel UA
J Clin Pharmacol; 2019 Oct; 59(10):1405-1414. PubMed ID: 31111505
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.
Wicha SG; Haak T; Zink K; Kees F; Kloft C; Kees MG
J Clin Pharmacol; 2015 Jun; 55(6):639-46. PubMed ID: 25600294
[TBL] [Abstract][Full Text] [Related]
4. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
[TBL] [Abstract][Full Text] [Related]
8. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
9. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
Landersdorfer CB; Kinzig M; Hennig FF; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F; Gusinde J
Antimicrob Agents Chemother; 2009 May; 53(5):2074-81. PubMed ID: 19223648
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
11. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
[TBL] [Abstract][Full Text] [Related]
12. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
[TBL] [Abstract][Full Text] [Related]
13. Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients.
Shen K; Yang M; Fan Y; Liang X; Chen Y; Wu J; Yu J; Zhang H; Wang R; Zhang F; Hang J; Wen X; Li H; Shen L; Zhang Z; Wu S; Shen B; Huang W; Chang C; Shen Y; Ren H; Yuan Q; Song X; Luo X; Zhang H; Yang W; Yang J; Zhang J
Clin Infect Dis; 2018 Nov; 67(suppl_2):S256-S262. PubMed ID: 30423042
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin dosing in post-bariatric surgery patients.
Colin P; Eleveld DJ; Struys MM; T'Jollyn H; Bortel LM; Ruige J; De Waele J; Van Bocxlaer J; Boussery K
Br J Clin Pharmacol; 2014 Jul; 78(1):84-93. PubMed ID: 24313873
[TBL] [Abstract][Full Text] [Related]
16. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
17. Penetration of meropenem into human pancreatic juice.
Ikawa K; Kondo N; Nakashima A; Yoshizawa K; Morikawa N; Ikeda K; Murakami Y; Ohge H; Sueda T
Scand J Infect Dis; 2013 May; 45(5):404-6. PubMed ID: 23176150
[TBL] [Abstract][Full Text] [Related]
18. Infection of the pancreatic duct following pancreas transplantation with bladder drainage.
Bonatti H; Steurer W; Konigsrainer A; Allerberger F; Margreiter R
J Chemother; 1995 Oct; 7(5):442-5. PubMed ID: 8596128
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of daptomycin in critically ill patients.
Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
